Ricerc@Sapienza

Up to date, screening for prostate cancer (PCa) remains one of the most appealing but also a very controversial topics in the
urological community. PCa is the second most common cancer in men worldwide and it is universally acknowledged as a complex
disease, with a multi-factorial etiology. The pathway of PCa diagnosis has changed dramatically in the last few years, with the
multiparametric magnetic resonance (mpMRI) playing a starring role with the introduction of the “MRI Pathway”. In this scenario the

Following exposure to human plasma (HP), nanoparticles (NPs) are coated with a biomolecular layer referred to as a protein corona. We recently revealed that characterizing the protein coronas of various NPs may provide a unique opportunity for cancer identification and discrimination. In other words, protein corona profiles of several NPs, when being analyzed using classifiers, would provide a unique "fingerprint"for each type of disease.

? The repair of inguinal hernias during Robot-assisted laparoscopic radical prostatectomy (RARP) has been published in several studies, which have demonstrated its effectiveness and safety . Overall, it has been observed that the hernioplasty adds on an average, 12–15 min in total surgical time . No significant difference was found between RARP with or without concomitant hernioplasty, with respect to hospitalization or bleeding complications . This procedure can be performed both robotically or laparoscopically depending on patient and surgeon preference.

Multiparametric magnetic resonance imaging (mpMRI) of the prostate has excellent sensitivity in detecting clinically significant prostate cancer (csPCa). Nevertheless, the clinical utility of negative mpMRI (nMRI) is less clearMultiparametric magnetic resonance imaging (mpMRI) of the prostate has excellent sensitivity in detecting clinically significant prostate cancer (csPCa). Nevertheless, the clinical utility of negative mpMRI (nMRI) is less clear. OBJECTIVE: To assess outcomes of men with nMRI and clinical follow-up after 7 yr of activity at a reference center.

PURPOSE: The aim of this study was to validate the role of MR/Ultrasound Fusion-Guided Targeted Biopsy as a first diagnostic modality in subjects with clinical suspicion of prostate cancer (PCa). MATERIALS AND METHODS: 108 men (age range 46-78 years) with clinical suspicion for PCa (PSA > 4 ng/mL) underwent multiparametric MRI of the prostate (mpMRI) and, when suspicious lesion were found (according to the PIRADSv2 scoring system), targeted biopsy was performed. All patients without significant alteration patterns at mpMRI have been referred for follow-up at 1 year.

Magnetic resonance imaging (MRI) targeted biopsy (TBx) of the prostate demonstrated to improve detection rate (DR) of clinically significant prostate cancer (csPCa) in biopsy-naive patients achieving strong level of evidence.

Objective: To investigate the current evidence that correlates impaired male fertility with the risk of developing male-related malignancies. Design: Systematic review and meta-analysis of population-based retrospective cohort studies. Setting: Not applicable. Patient(s): Men diagnosed with impaired fertility status and subsequently observed to determine incidence risk in developing testicular cancer (TCa) or prostate cancer (PCa). Intervention(s): Not applicable.

Purpose: Diagnosis of anterior prostate cancer (PCa) can be quite challenging, often leading to delay in treatment. mpMRI-guided biopsy (GB) has been introduced aiming to increase the number of diagnoses of clinically significant PCa with fewer cores. The aim of our study is to compare pathological findings of prostate biopsy, In-bore or Fusion technique, with histopathological evaluation of radical prostatectomy.

The aim of the study was to compare the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI), multiparametric ultrasound (mpUS) and US/MRI fusion imaging techniques in the detection of prostate cancer.

In the Prostate Imaging Reporting and Data System (PI-RADS) 3 population, the overall detection rates for prostate cancer (PC) and clinically significant PC (csPC) range from 10.3% to 55.8% and from 3.4% to 46.5%, respectively. Decision to perform only a targeted biopsy or a systematic biopsy should be associated with a lower detection rate of both PC and csPC. PI-RADS v1 or v2 seems to have no significant impact on biopsy outcomes. A prostate-specific antigen density of ≥0.15 ng/ml/ml may represent an index to decide whether to biopsy or not.